83458
document
Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen ( HBsAg ) vaccines . To study the regulation of the human immune response to hepatitis B surface antigen ( HBsAg ) we have carefully monitored the in vivo humoral and in vitro cellular immune responses to HBsAg in 50 subjects receiving four doses of hepatitis B vaccine according to a 0 , 1 , 2 , 12 month vaccination scheme . Twenty-three subjects were given a plasma-derived vaccine ( Hevac B ) and 27 received a recombinant HBsAg vaccine ( yeast-derived ; Engerix-B ) . The humoral and cellular immune responses were measured before vaccination ( day 0 ) ; 6 days after the second dose ( day 36 ) ; 6 days ( day 66 ) , 2 months ( day 120 ) and 10 months ( day 365 ) after the third dose and 1 month after the fourth dose ( day 395 ) . Based on the kinetics of the humoral immune responses , the vaccinees could be classified into fast , intermediate and slow/non-responders . Based on the magnitude of the immune response ( anti-HBs titre ) on day 395 , the vaccinees could be divided into high ( > or = 2000 U l-1 ) and low ( < or = 2000 U l-1 ) responders . A close correlation between the kinetics and the magnitude of the humoral immune response was observed . The in vivo anti-HBs response was measured using commercially available immunoradiometric assays . The in vitro cellular immune response was measured using an HBsAg-specific lymphoproliferation assay . Because of interassay variability the results were considered as dichotomous variables ( proliferation versus non-proliferation ) for further data analysis . A statistically significant correlation was observed between the kinetics and magnitude of the humoral immune response on the one hand and the in vitro anti-HBs response on the other hand . ( ABSTRACT TRUNCATED AT 250 WORDS )
83459
Intervention_Pharmacological
hepatitis B surface antigen ( HBsAg ) vaccines .
83460
Intervention_Pharmacological
hepatitis B surface antigen ( HBsAg )
83461
Intervention_Pharmacological
hepatitis B vaccine
83462
Intervention_Pharmacological
plasma-derived vaccine ( Hevac B )
83463
Intervention_Pharmacological
recombinant HBsAg vaccine ( yeast-derived ; Engerix-B ) .
83464
Outcome_Physical
humoral immune response
83465
Outcome_Physical
in vivo anti-HBs response
83466
Outcome_Physical
in vitro cellular immune response
83467
Outcome_Other
dichotomous variables
83468
Participant_Condition
human immune response to hepatitis B surface antigen
83469
Participant_Sample-size
50
83470
Participant_Condition
receiving four doses of hepatitis B vaccine